Status:
UNKNOWN
"NORPLASMA" Covid-19 Convalescent Plasma Treatment Monitoring Study
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
St. Olavs Hospital
Sykehuset Telemark
Conditions:
COVID
Eligibility:
All Genders
18+ years
Brief Summary
NORPLASMA COVID-19 includes both the production of convalescent plasma from approved blood donors who have recovered from covid-19 (coronavirus disease 2019), and clinical studies to evaluate efficacy...
Detailed Description
The NORPLASMA MONITOR study: Main hypothesis: Plasma from selected COVID-19 convalescent blood donors contain neutralizing/therapeutic antibodies against Severe acute respiratory syndrome coronavirus...
Eligibility Criteria
Inclusion
- patients treated with covid-19 convalescent plasma
- patients who has provided informed consent or where nearest relative has given consent
Exclusion
- patients included in other clinical studies of covid-19 treatment
- consent not given
- All eligible patients should be invited.
Key Trial Info
Start Date :
July 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04463823
Start Date
July 6 2020
End Date
May 31 2025
Last Update
December 5 2023
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Helse Fonna
Haugesund, Norway
2
Sorlandet hospital
Kristiansand, Norway
3
Akershus University Hospital
Lørenskog, Norway
4
Oslo University Hospital
Oslo, Norway